


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**COMPLETION OF ALL SUBJECTS ENROLLMENT IN THE PHASE III
REGISTRATIONAL CLINICAL TRIAL OF TQC3721 INHALATION SUSPENSION
“PDE3/4 INHIBITOR”**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that a Phase III pivotal registrational clinical trial (PACER-III) of TQC3721 inhalation suspension “PDE3/4 inhibitor”, a national Category 1 innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Group, for the maintenance treatment of chronic obstructive pulmonary disease (COPD), has recently completed the enrollment of all subjects.

TQC3721 inhalation suspension is a dual-target PDE3/4 inhibitor. Phosphodiesterases (PDEs) are an enzyme superfamily that regulates various pathological and physiological processes by catalysing the hydrolysis and inactivation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Among these, PDE3 is highly expressed in airway smooth muscle, while PDE4 is widely expressed in various types of inflammatory cells. TQC3721 exerts its effects through a dual mechanism: on the one hand, it promotes airway smooth muscle relaxation to improve ventilation; on the other hand, it inhibits the inflammatory response, thereby effectively controlling the progression of the disease.

COPD is a lung disease characterised by chronic respiratory symptoms (dyspnoea, cough and sputum production), with chronic airway inflammation and persistent airflow obstruction as its core pathological mechanisms. COPD is the third leading cause of death worldwide, with more than 391 million patients. Current treatment for COPD primarily relies on long-acting muscarinic antagonists (LAMAs) and long-acting β 2-adrenergic agonists (LABAs), which can improve lung function but have limited efficacy against airway inflammation. Inhaled corticosteroids (ICS), as a primary treatment for chronic inflammatory airway diseases, can reduce acute exacerbations when used in combination with LABAs or LAMAs. However, they offer limited benefit to patients with low blood eosinophil counts and increase the risk of pneumonia. Consequently, there is an urgent need to develop novel drugs that combine anti-inflammatory effects with the ability to improve airflow obstruction.

As an innovative inhalation formulation, TQC3721 has been developed in two formulations – a nebulised inhalation suspension and a dry powder inhalation – catering to different patient populations, disease severity levels and commercial application scenarios. In the context of COPD, TQC3721 nebulised inhalation suspension has demonstrated best-in-class potential in Phase II studies^[1, 2]. This formulation has now completed Phase III clinical enrollment, while the dry powder inhalation formulation is concurrently advancing to Phase II clinical trials, it is expected to become the first domestically developed inhaled PDE3/4 dual inhibitor approved in China.

Sources:

- [1] Luo Z, et al. TQC3721 in COPD: A Phase 2, Multicentre, Randomised, Double-Blind Trial [Poster]. ERS 2025, Amsterdam, Sept 2025.
- [2] He LX, Yang L, Xiao ZK, et al. Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II): A Phase 2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial. Chest. 2026;169(6):1536-1550. doi:10.1016/j.chest.2025.12.055

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 8 October 2026

As at the date of this announcement, the Board of the Company comprises five executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive Directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.